Iqvia Holdings Inc (NYSE:IQV) Shares Purchased by Valeo Financial Advisors LLC

Valeo Financial Advisors LLC increased its position in shares of Iqvia Holdings Inc (NYSE:IQV) by 8.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,230 shares of the medical research company’s stock after acquiring an additional 180 shares during the period. Valeo Financial Advisors LLC’s holdings in Iqvia were worth $333,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Oppenheimer & Co. Inc. lifted its stake in Iqvia by 2.0% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 5,322 shares of the medical research company’s stock worth $856,000 after acquiring an additional 102 shares in the last quarter. Parallel Advisors LLC raised its position in Iqvia by 27.0% in the 2nd quarter. Parallel Advisors LLC now owns 512 shares of the medical research company’s stock valued at $82,000 after purchasing an additional 109 shares in the last quarter. APG Asset Management N.V. raised its position in Iqvia by 120.8% in the 2nd quarter. APG Asset Management N.V. now owns 34,000 shares of the medical research company’s stock valued at $4,804,000 after purchasing an additional 18,600 shares in the last quarter. National Asset Management Inc. raised its position in Iqvia by 6.6% in the 2nd quarter. National Asset Management Inc. now owns 3,787 shares of the medical research company’s stock valued at $610,000 after purchasing an additional 234 shares in the last quarter. Finally, Flinton Capital Management LLC raised its position in Iqvia by 455.3% in the 2nd quarter. Flinton Capital Management LLC now owns 85,988 shares of the medical research company’s stock valued at $13,836,000 after purchasing an additional 70,504 shares in the last quarter. 89.80% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms have issued reports on IQV. Mizuho raised Iqvia from a “neutral” rating to a “buy” rating and increased their price target for the company from $150.00 to $175.00 in a research report on Friday, June 21st. Credit Suisse Group increased their price target on Iqvia from $165.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. SunTrust Banks increased their price target on Iqvia from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Morgan Stanley increased their price target on Iqvia from $156.00 to $170.00 and gave the company an “overweight” rating in a research report on Wednesday, June 19th. Finally, Barclays set a $180.00 price target on Iqvia and gave the company a “buy” rating in a research report on Monday, July 15th. Four investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Iqvia presently has a consensus rating of “Buy” and a consensus price target of $163.09.

Shares of NYSE IQV opened at $144.83 on Thursday. The company has a debt-to-equity ratio of 1.72, a quick ratio of 1.14 and a current ratio of 1.14. Iqvia Holdings Inc has a fifty-two week low of $104.90 and a fifty-two week high of $164.13. The firm has a market capitalization of $28.67 billion, a PE ratio of 28.29, a price-to-earnings-growth ratio of 1.62 and a beta of 0.89. The stock’s 50-day simple moving average is $150.88 and its 200-day simple moving average is $147.91.

Iqvia (NYSE:IQV) last issued its earnings results on Wednesday, July 24th. The medical research company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $1.38 by $0.01. Iqvia had a return on equity of 15.95% and a net margin of 2.31%. The business had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.70 billion. During the same quarter last year, the company earned $1.29 EPS. The business’s quarterly revenue was up 6.7% on a year-over-year basis. On average, sell-side analysts forecast that Iqvia Holdings Inc will post 5.88 earnings per share for the current fiscal year.

In other news, insider Kevin C. Knightly sold 6,945 shares of the firm’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $158.53, for a total transaction of $1,100,990.85. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Kevin C. Knightly sold 4,278 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $158.50, for a total value of $678,063.00. Following the sale, the insider now directly owns 4,084 shares in the company, valued at approximately $647,314. The disclosure for this sale can be found here. Insiders have sold a total of 2,627,251 shares of company stock worth $412,103,046 in the last three months. Corporate insiders own 6.00% of the company’s stock.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read More: Limitations of analyzing profit margin

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.